• Dobson, Simon


    Investigator, BC Children's Hospital
    Clinical Associate Professor, Department of Pediatrics, University of British Columbia

    Degrees / Designations
    MA, MBBS, MD
    Primary Area of Research
    Evidence to Innovation
    Secondary Area(s) of Research
    Lab Phone
    Mailing Address

    BC Children's Hospital Ambulatory Care Building
    Room K4-221
    4480 Oak St. 
    Vancouver, BC  V6H 3V4

    Research Areas
    • Infections and Inflammatory Diseases
    • Immunization

    Immunization for children has been the greatest advance in child health in the last sixty years after the provision of clean water and food. As the understanding of protection against infectious agents has improved, so new vaccines are developed by industry and then carefully tested in humans through a graded process of clinical trials. As a member of the Vaccine Evaluation Centre, I have lead many trials of new vaccines and combinations of vaccines for children and adolescents.

    Since vaccines are given to entirely healthy children, they have to be safe and the public has to have confidence in their safety. Exploring vaccine adverse events and explaining their mechanisms are other areas of research interest. Investigating the attitudes, knowledge and beliefs of parents, especially the reluctant immunizers, is an important emerging and evolving area of quantitative research also.

    Current Projects

    1) A multi-year study of reducing the number of doses of Human Papillomavirus vaccines from three to two. HPV vaccines are a boon to womens' health offering primary prevention of cervical cancer. However, the vaccine is expensive in a three dose schedule and this limits the extent of its use in even affluent societies, let alone in the developing world. The provinces of BC, Quebec and Nova Scotia have combined their resources to fund a study looking at the non-inferiority in immunogenicity of 2 doses given to 9-13 year old girls compared to 3 doses given to 16-25 year old young women and to a second control group of 9-13 year old girls.

    2) Ongoing rapid influenza vacine trials in young children. Assuring vaccine safety and immunogenicity in a pandemic influenza situation, requires that there be infrastructure, research protocols and appropriately trained staff ready to do accurate and efficient clinical trials. Given the experience of PH1N1 inluenza vaccine roll out in the Fall of 2009, the next challenge is to ensure seasonal influenza vaccine safety and immunogenecity in the Fall of 2010. To this end a series of trials will be done at the Vaccine Evaluation Centre in the late Summer of 2010.

    Selected Publications

    Dobson S, McNeil S, Dionne M, et al. Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial. JAMA. 2013 May 1;309(17):1793-1802.

    Zhuo L, Quynh D, Dobson S. Determinants of influenza immunization uptake in Canadian youths. Vaccine. 2010 April 26;28:3462-3466.

    Perrett KP. Snape MD. Ford KJ. John TM. Yu LM. Langley JM. McNeil S. Dull PM. Ceddia F. Anemona A. Halperin SA. Dobson S. Pollard AJ. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatric Infectious Disease Journal. 2009;28:186-93.

    Doan QH. Kissoon N. Dobson S. Whitehouse S. Cochrane D. Schmidt B. Thomas E. A randomized, controlled trial of the impact of early and rapid diagnosis of viral infections in children brought to an emergency department with febrile respiratory tract illnesses. Journal of Pediatrics. 2009;154:91-5.

    Ogilvie GS. Remple VP. Marra F. McNeil SA. Naus M. Pielak K. Ehlen T. Dobson S. Patrick DM. Money DM.  Intention of parents to have male children vaccinated with the human papillomavirus vaccine. Sexually Transmitted Infections. 2008;318-23.

    Gunther OP. Ogilvie G. Naus M. Young E. Patrick DM. Dobson S. Duval B. Noel PA. Marra F. Miller D. Brunham RC. Pourbohloul B. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity? Journal of Infectious Diseases. 2008;197:1653-61.

    Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008 Jan 9;299(2):173-84.

    Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, Pielak KL, Ehlen TG, Dobson SR, Money DM, Patrick DM. Parental intention to have daughters receive the human papillomavirus vaccine. CMAJ. 2007 Dec 4;177(12):1506-12.

    Halperin S, Dobson S, Eiden, J, Gennevois, D, Langley J, Levitt, D, McCall-Sani R, McNeil S, Smith B, Van Nest G. Comparison of the Safety and Immunogenicity of Hepatitis B Virus Surface Antigen Co-administered with an Immunostimulatory Phosphorothioate Oligonucleotide and a Licensed Hepatitis B Vaccine in Healthy Young Adults. Vaccine. 2006 Jan 9;24(1): 20-26.

    Lee BE. Chawla R. Langley JM. Forgie SE. Al-Hosni M. Baerg K. Husain E. Strong J. Robinson JL. Allen U. Law BJ. Dobson S. Davies HD. Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of aseptic meningitis. BMC Infectious Diseases. 2006;6:68.

    Pollard AJ,  Ochnio J, Ho M, Callaghan M, Bigham M, Dobson S. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerg Infect Dis. 2004 Oct 1;10(10): 1812-5.


    Chiron. Phase II.Trial of a Conjugate Meningococcal ACWY Vaccine for Infants. $400,000 2004-2006 S. Dobson

    Michael Smith Foundation for Health Research. Unclogging the Pediatric Emergency Room. $100,000 2005-2007 S. Dobson

    Michael Smith Foundation for Health Research. A Controlled Trial to Assess the Immunogenicity of a Proposed Pediatric Dosing Schedule of Human Papilloma Virus Vaccine. $1,800,000 2007- 2010 S. Dobson

    Honours & Awards

    PHSA Plus Award, Individual - 2014

    Research Group Members